Growth Metrics

Novavax (NVAX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $15.2 million.

  • Novavax's Accounts Payables fell 7352.61% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 7352.61%. This contributed to the annual value of $41.6 million for FY2024, which is 6864.57% down from last year.
  • Novavax's Accounts Payables amounted to $15.2 million in Q3 2025, which was down 7352.61% from $50.6 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Accounts Payables ranged from a high of $386.5 million in Q2 2022 and a low of $15.2 million during Q3 2025
  • Moreover, its 5-year median value for Accounts Payables was $87.2 million (2023), whereas its average is $107.4 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first skyrocketed by 441171.56% in 2021, then plummeted by 7742.59% in 2023.
  • Novavax's Accounts Payables (Quarter) stood at $127.0 million in 2021, then soared by 70.42% to $216.5 million in 2022, then plummeted by 38.75% to $132.6 million in 2023, then tumbled by 68.65% to $41.6 million in 2024, then plummeted by 63.38% to $15.2 million in 2025.
  • Its Accounts Payables stands at $15.2 million for Q3 2025, versus $50.6 million for Q2 2025 and $34.2 million for Q1 2025.